Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial-Reference-Cited by-同舟云学术

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Published:2019-12 Issue:12 Volume:20 Page:1730-1739
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Khalaf Daniel J,Annala Matti,Taavitsainen Sinja,Finch Daygen L,Oja Conrad,Vergidis Joanna,Zulfiqar Muhammad,Sunderland Katherine,Azad Arun A,Kollmannsberger Christian K,Eigl Bernhard J,Noonan Krista,Wadhwa Deepa,Attwell Andrew,Keith Bruce,Ellard Susan L,Le Lyly,Gleave Martin E,Wyatt Alexander W,Chi Kim N

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. The physical burden of prostate cancer;Penson;Urol Clin North Am,2003

2. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer;Watson;Nat Rev Cancer,2015

3. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer;Attard;BJU Int,2005

4. Development of a second-generation antiandrogen for treatment of advanced prostate cancer;Tran;Science,2009

5. Second-line hormonal therapy for men with chemotherapy-naive, castration-resistant prostate cancer: American Society of Clinical Oncology provisional clinical opinion;Virgo;J Clin Oncol,2017

Cited by 254 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

3. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

4. Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer;International Journal of Molecular Sciences;2024-08-26

5. Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial;Journal of Clinical Oncology;2024-08-20